Shield Therapeutics reported a 41% increase in revenue to $30.4 million in the first half of 2026, boosted by a $7.9 million milestone payment from partner ASK and higher royalties. Despite this, group revenue and ACCRUFeR net revenue declined due to softer second-quarter trading and changes in Medicaid prescription rules affecting prices. The company shifted focus to commercial patients, growing that segment by 27%, with total prescriptions up 21%. Cash reserves fell to $8.3 million by June, and the company secured a new contract expanding clinic access. Shares fell 20.5% following the report, while the company remains on track for profitability in 2026.
SK Hynix shares rose 7% and Seagate climbed 5% on a strong buying wave across the memory and storage sector, even as the broader market declined. The Roundhill Memory ETF gained 5%, highlighting growing demand for high-bandwidth memory used in AI and...
Seagate Technology shares have soared 385.3% over the past year, driven by strong demand for AI-related data storage from hyperscale data centers. The company reported a 34% revenue increase in fiscal 2026 and doubled net income, with analysts foreca...
